Immunobiological characterization of cancer stem cells isolated from glioblastoma patients

Tiziano Di Tomaso, Stefania Mazzoleni, Ena Wang, Gloria Sovena, Daniela Clavenna, Alberto Franzin, Pietro Mortini, Soldano Ferrone, Claudio Doglioni, Francesco M. Marincola, Rossella Galli, Giorgio Parmiani, Cristina Maccalli

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Purpose: Cancer stem cells (CSC) have been isolated from human tumors, including glioblastoma multiforme (GBM). The aims of this study were the immunobiological characterization of GBM CSCs and the assessment of whether these cells represent suitable targets for immunotherapy. Experimental Design: GBM CSC lines and their fetal bovine serum (FBS)-cultured non-CSC pair lines were generated and examined by flow cytometry for expression of known tumor antigens, MHC-I and MHC-II molecules, antigen-processing machinery components, and NKG2D ligands. In addition, immunogenicity and immunosuppression of such cell lines for autologous or allogeneic T lymphocytes were tested by cytokine secretion (ELISPOT) or proliferation (carboxyfluorescein diacetate succinimidyl ester) assays, respectively. Results: Both GBM CSC and FBS lines were weakly positive and negative for MHC-I, MHC-II, and NKG2D ligand molecules, respectively. Antigen-processing machinery molecules were also defective in both cell types. Upregulation of most molecules was induced by IFNs or 5-Aza deoxycytidine, although more efficiently in FBS than in CSCs. Patient T-cell responses, mediated by both TH1 and the TH2 subsets, against autologous CSC could be induced in vitro. In addition, CSC but not their paired FBS tumor lines inhibited T-cell proliferation of healthy donors. Notably, a differential gene signature that was confirmed at the protein levels for some immunologic-related molecules was also found between CSC and FBS lines. Conclusions: These results indicate lower immunogenicity and higher suppressive activity of GBM CSC compared with FBS lines. The immunogenicity, however, could be rescued by immune modulation leading to anti-GBM T cell-mediated immune response.

Original languageEnglish
Pages (from-to)800-813
Number of pages14
JournalClinical Cancer Research
Volume16
Issue number3
DOIs
Publication statusPublished - 1 Feb 2010
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Glioblastoma
Serum
T-Lymphocytes
Antigen Presentation
Cell Line
Ligands
Enzyme-Linked Immunospot Assay
Deoxycytidine
Neoplasm Antigens
Immunotherapy
Immunosuppression
Neoplasms
Flow Cytometry
Research Design
Up-Regulation
Stem Cells
Cell Proliferation
Tissue Donors
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. / Di Tomaso, Tiziano; Mazzoleni, Stefania; Wang, Ena; Sovena, Gloria; Clavenna, Daniela; Franzin, Alberto; Mortini, Pietro; Ferrone, Soldano; Doglioni, Claudio; Marincola, Francesco M.; Galli, Rossella; Parmiani, Giorgio; Maccalli, Cristina.

In: Clinical Cancer Research, Vol. 16, No. 3, 01.02.2010, p. 800-813.

Research output: Contribution to journalArticle

Di Tomaso, T, Mazzoleni, S, Wang, E, Sovena, G, Clavenna, D, Franzin, A, Mortini, P, Ferrone, S, Doglioni, C, Marincola, FM, Galli, R, Parmiani, G & Maccalli, C 2010, 'Immunobiological characterization of cancer stem cells isolated from glioblastoma patients', Clinical Cancer Research, vol. 16, no. 3, pp. 800-813. https://doi.org/10.1158/1078-0432.CCR-09-2730
Di Tomaso, Tiziano ; Mazzoleni, Stefania ; Wang, Ena ; Sovena, Gloria ; Clavenna, Daniela ; Franzin, Alberto ; Mortini, Pietro ; Ferrone, Soldano ; Doglioni, Claudio ; Marincola, Francesco M. ; Galli, Rossella ; Parmiani, Giorgio ; Maccalli, Cristina. / Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 3. pp. 800-813.
@article{14119cb8a5fb4de2baf641d51b7a7248,
title = "Immunobiological characterization of cancer stem cells isolated from glioblastoma patients",
abstract = "Purpose: Cancer stem cells (CSC) have been isolated from human tumors, including glioblastoma multiforme (GBM). The aims of this study were the immunobiological characterization of GBM CSCs and the assessment of whether these cells represent suitable targets for immunotherapy. Experimental Design: GBM CSC lines and their fetal bovine serum (FBS)-cultured non-CSC pair lines were generated and examined by flow cytometry for expression of known tumor antigens, MHC-I and MHC-II molecules, antigen-processing machinery components, and NKG2D ligands. In addition, immunogenicity and immunosuppression of such cell lines for autologous or allogeneic T lymphocytes were tested by cytokine secretion (ELISPOT) or proliferation (carboxyfluorescein diacetate succinimidyl ester) assays, respectively. Results: Both GBM CSC and FBS lines were weakly positive and negative for MHC-I, MHC-II, and NKG2D ligand molecules, respectively. Antigen-processing machinery molecules were also defective in both cell types. Upregulation of most molecules was induced by IFNs or 5-Aza deoxycytidine, although more efficiently in FBS than in CSCs. Patient T-cell responses, mediated by both TH1 and the TH2 subsets, against autologous CSC could be induced in vitro. In addition, CSC but not their paired FBS tumor lines inhibited T-cell proliferation of healthy donors. Notably, a differential gene signature that was confirmed at the protein levels for some immunologic-related molecules was also found between CSC and FBS lines. Conclusions: These results indicate lower immunogenicity and higher suppressive activity of GBM CSC compared with FBS lines. The immunogenicity, however, could be rescued by immune modulation leading to anti-GBM T cell-mediated immune response.",
author = "{Di Tomaso}, Tiziano and Stefania Mazzoleni and Ena Wang and Gloria Sovena and Daniela Clavenna and Alberto Franzin and Pietro Mortini and Soldano Ferrone and Claudio Doglioni and Marincola, {Francesco M.} and Rossella Galli and Giorgio Parmiani and Cristina Maccalli",
year = "2010",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-09-2730",
language = "English",
volume = "16",
pages = "800--813",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Immunobiological characterization of cancer stem cells isolated from glioblastoma patients

AU - Di Tomaso, Tiziano

AU - Mazzoleni, Stefania

AU - Wang, Ena

AU - Sovena, Gloria

AU - Clavenna, Daniela

AU - Franzin, Alberto

AU - Mortini, Pietro

AU - Ferrone, Soldano

AU - Doglioni, Claudio

AU - Marincola, Francesco M.

AU - Galli, Rossella

AU - Parmiani, Giorgio

AU - Maccalli, Cristina

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Purpose: Cancer stem cells (CSC) have been isolated from human tumors, including glioblastoma multiforme (GBM). The aims of this study were the immunobiological characterization of GBM CSCs and the assessment of whether these cells represent suitable targets for immunotherapy. Experimental Design: GBM CSC lines and their fetal bovine serum (FBS)-cultured non-CSC pair lines were generated and examined by flow cytometry for expression of known tumor antigens, MHC-I and MHC-II molecules, antigen-processing machinery components, and NKG2D ligands. In addition, immunogenicity and immunosuppression of such cell lines for autologous or allogeneic T lymphocytes were tested by cytokine secretion (ELISPOT) or proliferation (carboxyfluorescein diacetate succinimidyl ester) assays, respectively. Results: Both GBM CSC and FBS lines were weakly positive and negative for MHC-I, MHC-II, and NKG2D ligand molecules, respectively. Antigen-processing machinery molecules were also defective in both cell types. Upregulation of most molecules was induced by IFNs or 5-Aza deoxycytidine, although more efficiently in FBS than in CSCs. Patient T-cell responses, mediated by both TH1 and the TH2 subsets, against autologous CSC could be induced in vitro. In addition, CSC but not their paired FBS tumor lines inhibited T-cell proliferation of healthy donors. Notably, a differential gene signature that was confirmed at the protein levels for some immunologic-related molecules was also found between CSC and FBS lines. Conclusions: These results indicate lower immunogenicity and higher suppressive activity of GBM CSC compared with FBS lines. The immunogenicity, however, could be rescued by immune modulation leading to anti-GBM T cell-mediated immune response.

AB - Purpose: Cancer stem cells (CSC) have been isolated from human tumors, including glioblastoma multiforme (GBM). The aims of this study were the immunobiological characterization of GBM CSCs and the assessment of whether these cells represent suitable targets for immunotherapy. Experimental Design: GBM CSC lines and their fetal bovine serum (FBS)-cultured non-CSC pair lines were generated and examined by flow cytometry for expression of known tumor antigens, MHC-I and MHC-II molecules, antigen-processing machinery components, and NKG2D ligands. In addition, immunogenicity and immunosuppression of such cell lines for autologous or allogeneic T lymphocytes were tested by cytokine secretion (ELISPOT) or proliferation (carboxyfluorescein diacetate succinimidyl ester) assays, respectively. Results: Both GBM CSC and FBS lines were weakly positive and negative for MHC-I, MHC-II, and NKG2D ligand molecules, respectively. Antigen-processing machinery molecules were also defective in both cell types. Upregulation of most molecules was induced by IFNs or 5-Aza deoxycytidine, although more efficiently in FBS than in CSCs. Patient T-cell responses, mediated by both TH1 and the TH2 subsets, against autologous CSC could be induced in vitro. In addition, CSC but not their paired FBS tumor lines inhibited T-cell proliferation of healthy donors. Notably, a differential gene signature that was confirmed at the protein levels for some immunologic-related molecules was also found between CSC and FBS lines. Conclusions: These results indicate lower immunogenicity and higher suppressive activity of GBM CSC compared with FBS lines. The immunogenicity, however, could be rescued by immune modulation leading to anti-GBM T cell-mediated immune response.

UR - http://www.scopus.com/inward/record.url?scp=76049114698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049114698&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-2730

DO - 10.1158/1078-0432.CCR-09-2730

M3 - Article

VL - 16

SP - 800

EP - 813

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -